Corcept Q4 Net Income Lower, Revenue Rises; Sets Guidance-March 2024-www.financetom.com

Corcept Q4 Net Income Lower, Revenue Rises; Sets Guidance

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Corcept Q4 Net Income Lower, Revenue Rises; Sets Guidance

Feb 26, 2025 2:26 PM

04:56 PM EST, 02/26/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) reported Q4 net income late Wednesday of $0.26 per diluted share, down from $0.28 a year earlier.

Revenue for the quarter ended Dec. 31 was $181.9 million, up from $135.4 million a year earlier.

Analysts surveyed by FactSet expected $198.7 million.

The company said it expects 2025 revenue of $900 million to $950 million. Analysts expected $841.6 million.

Previous page： Americas Gold and Silver Trims Q3 Net Loss Next page： Bicara Therapeutics' Q3 Net Loss Narrows

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Americas Gold and Silver Trims Q3 Net Loss

Nov 10, 2025

08:17 AM EST, 11/10/2025 (MT Newswires) -- Americas Gold and Silver ( USAS ) traded 2.8% higher at last look Monday in NYSE American pre-market trading as the company trimmed its net loss for the third quarter. The company posted an adjusted loss of US$4.3 million, or a loss of $0.02 per share, compared to a year-ago net loss of...

Bicara Therapeutics' Q3 Net Loss Narrows

Nov 10, 2025

08:16 AM EST, 11/10/2025 (MT Newswires) -- Bicara Therapeutics ( BCAX ) reported a Q3 net loss Monday of $0.67 per diluted share, narrowing from a loss of $1.60 a year earlier. Analysts surveyed by FactSet expected a loss of $0.54. As of Sept. 30, the company had $407.6 million in cash and cash equivalents, which it said is expected...

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline

Nov 10, 2025

MELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ( PPCB ) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC (Hexstone), a family office that has invested in a significant number of Digital...

Visa, Mastercard reach revised swipe-fee settlement with merchants

Nov 10, 2025

* Card processing fees would be lowered for five years * Merchants can choose what types of cards to accept * Settlement would replace rejected $30 billion accord By Jonathan Stempel NEW YORK, Nov 10 (Reuters) - Visa and Mastercard ( MA ) announced a revised settlement with merchants who accused the card networks of charging too much to accept...